| Index | — | P/E | 21.33 | EPS (ttm) | 0.55 | Insider Own | 2.59% | Shs Outstand | 141.05M | Perf Week | -3.69% |
| Market Cap | 1.65B | Forward P/E | 9.96 | EPS next Y | 1.18 | Insider Trans | 0.58% | Shs Float | 21.99M | Perf Month | 13.44% |
| Enterprise Value | 3.20B | PEG | 1.32 | EPS next Q | 0.23 | Short Float | 17.07% | Perf Quarter | 9.12% | ||
| Income | 79.00M | P/S | 0.26 | EPS this Y | -9.99% | Short Ratio | 8.20 | Perf Half Y | 17.54% | ||
| Sales | 6.41B | P/B | 0.95 | EPS next Y | 24.91% | ROA | 1.48% | Short Interest | 3.75M | Perf YTD | 32.84% |
| Book/sh | 12.38 | P/C | 2.29 | EPS next 5Y | 16.17% | ROE | 5.21% | 52W High | 14.99 -22.41% | Perf Year | -19.55% |
| Cash/sh | 5.13 | P/FCF | 5.50 | EPS past 3/5Y | -10.07% — | ROIC | 9.26% | 52W Low | 7.71 50.84% | Perf 3Y | — |
| Dividend Est. | — | EV/EBITDA | 7.95 | Sales past 3/5Y | 7.22% — | Gross Margin | 29.96% | Volatility | 4.06% 3.80% | Perf 5Y | — |
| Dividend TTM | — | EV/Sales | 0.50 | EPS Y/Y TTM | -70.43% | Oper. Margin | 7.54% | ATR (14) | 0.44 | Perf 10Y | — |
| Dividend Ex-Date | — | Quick Ratio | 1.99 | Sales Y/Y TTM | 3.36% | Profit Margin | 1.22% | RSI (14) | 51.97 | Recom | 2.42 |
| Dividend Gr. 3/5Y | — | Current Ratio | 2.10 | EPS Q/Q | -76.92% | SMA20 | -0.49% | Beta | 1.06 | Target Price | 12.67 |
| Payout | 0.00% | Debt/Eq | 1.30 | Sales Q/Q | -1.40% | SMA50 | 4.93% | Rel Volume | 0.85 | Prev Close | 11.73 |
| Employees | 22,350 | LT Debt/Eq | 1.28 | Earnings | Nov 04 | SMA200 | 17.33% | Avg Volume | 430.93K | Price | 11.63 |
| IPO Date | Jul 18, 2024 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -33.97% 2.05% | Net Debt/EBITDA | 3.84 | Volume | 368,250 | Change | -0.85% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-22-26 | Initiated | BMO Capital | Market Perform | $11 |
| Aug-06-26 | Reiterated | Goldman Sachs | $11 → $13 | |
| Aug-06-26 | Reiterated | Guggenheim | Buy | $14 |
| Dec-18-25 | Reiterated | Mizuho | Outperform | $13 → $12 |
| Dec-18-25 | Reiterated | UBS | Buy | $17 → $14 |
| Nov-18-25 | Reiterated | Mizuho | Outperform | $20 → $13 |
| Nov-17-25 | Downgrade | Keybanc | Overweight → Sector Weight | |
| Nov-14-25 | Reiterated | Leerink Partners | Outperform | $23 → $16 |
| Nov-14-25 | Reiterated | RBC Capital | Outperform | $21 → $16 |
| Nov-14-25 | Downgrade | Morgan Stanley | Overweight → Equal Weight | $27 → $12 |
Ardent Health, Inc. owns and operates a network of hospitals and clinics that provides healthcare services in the United States. The company offers general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services within inpatient and ambulatory care settings. It also operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers, urgent care centers, free-standing emergency departments, and diagnostic imaging centers. The company operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. Ardent Health, Inc. was formerly known as Ardent Health Partners, Inc. and changed its name to Ardent Health, Inc. in June 2025. The company was founded in 2001 and is based in Brentwood, Tennessee. Ardent Health, Inc. is a subsidiary of EGI-AM Investments, L.L.C.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | FY 2016 12/31/2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6,406 | 6,324 | 5,966 | 5,409 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 4,487 | 156 | 1,033 | 141 | — | — | — | — | — | |
| Gross Profit | 1,919 | 6,169 | 4,933 | 5,269 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,021 | 1,193 | 3,885 | 3,623 | — | — | — | — | — | |
| Research and Development | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Other Operating Expense | 414 | 4,650 | 642 | 1,416 | — | — | — | — | — | |
| Operating Income | 483 | 326 | 406 | 230 | — | — | — | — | — | |
| Interest Expense | 50 | 55 | 66 | 65 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -226 | 16 | 23 | -12 | — | — | — | — | — | |
| Net Income Before Taxes | 208 | 286 | 363 | 152 | — | — | — | — | — | |
| Income Taxes | 40 | 56 | 63 | 23 | — | — | — | — | — | |
| Consolidated Net Income | 79 | 136 | 210 | 50 | — | — | — | — | — | |
| Net Income From Continuing Operations | 168 | 230 | 300 | 129 | — | — | — | — | — | |
| Net Income | 79 | 136 | 210 | 50 | — | — | — | — | — | |
| EPS (Recurring) | 0.55 | 0.96 | 1.59 | 0.35 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 0.55 | 0.96 | 1.59 | 0.35 | — | — | — | — | — | |
| EPS (Diluted) | 0.55 | 0.96 | 1.58 | 0.35 | — | — | — | — | — | |
| EBITDA | 402 | 497 | 575 | 350 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 21.15 | 9.20 | 10.81 | — | — | — | — | — | — | |
| Price To Sales Ratio | 0.26 | 0.20 | 0.38 | — | — | — | — | — | — | |
| Gross Margin | 29.96 | 97.55 | 82.69 | 97.41 | — | — | — | — | — | |
| Operating Margin | 7.54 | 5.15 | 6.81 | 4.25 | — | — | — | — | — | |
| Net Margin | 1.23 | 2.15 | 3.52 | 0.92 | — | — | — | — | — | |
| Shares Outstanding | 142 | 141 | 132 | 143 | — | — | — | — | — | |
| Market Capitalization | 1,651 | 1,245 | 2,255 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| LUMSDAINE ALFRED | Chief Financial Officer | Jun 05 '26 | Buy | 8.81 | 10,000 | 88,100 | 329,183 | Jun 08 |
| DeMichiei Robert | Director | Jun 05 '26 | Buy | 8.73 | 11,260 | 98,300 | 35,564 | Jun 08 |
| Webb Robert Thomas | Director | Nov 08 '24 | Buy | 16.98 | 20,000 | 339,600 | 40,275 | Nov 13 |